−2.75TWD
−166.27 MTWD
225.46 MTWD
35.30 M
About GENEREACH BIOTECHNOLOGY CORP
Sector
Industry
CEO
Hsiao-Fen Chang
Website
Headquarters
Taichung
Founded
2004
ISIN
TW0004171004
FIGI
BBG003MBY5Y8
GeneReach Biotechnology Corp. develops, manufactures and markets products for applied nucleic acid detection technology. The company mainly involves in the manufacture of animal drugs & chemical products, medical equipment, general instrument and provides biotechnology services. It offers complete disease management solution for the aquaculture farming industry, such as polymerase chain reaction detection kit, robust mobile polymerase chain reaction detection system; in-clinic nucleic acid detection system for companion animal health management and total deoxyribonucleic acid extraction kit used for nucleic acid automatic extraction system. GeneReach Biotechnology was founded by Cheng Chung Liu on November 12, 2004 and is headquartered in Taichung, Taiwan.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 4171 is 31.80 TWD — it has increased by 1.76% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on TPEX exchange GENEREACH BIOTECHNOLOGY CORP stocks are traded under the ticker 4171.
GENEREACH BIOTECHNOLOGY CORP is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
4171 stock is 1.91% volatile and has beta coefficient of 0.16. Check out the list of the most volatile stocks — is GENEREACH BIOTECHNOLOGY CORP there?
4171 earnings for the last quarter are 0.26 TWD per share, whereas the estimation was 0.34 TWD resulting in a −24.49% surprise. The estimated earnings for the next quarter are 0.23 TWD per share. See more details about GENEREACH BIOTECHNOLOGY CORP earnings.
GENEREACH BIOTECHNOLOGY CORP revenue for the last quarter amounts to 123.00 M TWD despite the estimated figure of 78.00 M TWD. In the next quarter revenue is expected to reach 129.00 M TWD.
Yes, you can track GENEREACH BIOTECHNOLOGY CORP financials in yearly and quarterly reports right on TradingView.
4171 stock has risen by 1.11% compared to the previous week, the month change is a 7.29% fall, over the last year GENEREACH BIOTECHNOLOGY CORP has showed a 29.65% decrease.
4171 net income for the last quarter is −58.22 M TWD, while the quarter before that showed −24.73 M TWD of net income which accounts for −135.36% change. Track more GENEREACH BIOTECHNOLOGY CORP financial stats to get the full picture.
Today GENEREACH BIOTECHNOLOGY CORP has the market capitalization of 1.76 B, it has decreased by 0.49% over the last week.
Yes, 4171 dividends are paid annually. The last dividend per share was 1.50 TWD. As of today, Dividend Yield (TTM)% is 3.92%. Tracking GENEREACH BIOTECHNOLOGY CORP dividends might help you take more informed decisions.
Like other stocks, 4171 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENEREACH BIOTECHNOLOGY CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GENEREACH BIOTECHNOLOGY CORP technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GENEREACH BIOTECHNOLOGY CORP stock shows the sell signal. See more of GENEREACH BIOTECHNOLOGY CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GENEREACH BIOTECHNOLOGY CORP EBITDA is −160.40 M TWD, and current EBITDA margin is −71.14%. See more stats in GENEREACH BIOTECHNOLOGY CORP financial statements.